- 1、本文档共171页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
课件:MM的整体治疗.ppt
* * * * * * * * * * * * * * * Panel A shows the time to disease progression on the basis of assessment by the investigators; the median time to progression was 24.0 months in the bortezomib group and 16.6 months in the control group (hazard ratio in the bortezomib group, 0.48). According to algorithmic analysis, the median time to progression was 20.7 months in the bortezomib group and 15.0 months in the control group (hazard ratio in the bortezomib group, 0.54; P0.001). Panel B shows overall survival after a median follow-up of 16.3 months. Median survival was not reached in either group. During that time, 45 patients (13%) in the bortezomib group and 76 patients (22%) in the control group died (hazard ratio in the bortezomib group, 0.61). * OS on an ITT basis after median follow-up of 36.7 mo (or 3 years). Median number of treatment cycles administered: 9 in VMP (50 weeks) versus 8 in MP (48 weeks). VMP arm had 35% reduction in death versus MP. Three y OS: 68 % versus 54% OS in patients who had received subsequent therapy Survival from start of second-line therapy for all patients receiving second-line therapy Survival from start of second-line therapy for all patients receiving novel agents Conclusion: by giving VMP upfront there were no more agressive relapses GIMEMA(VMPT-VT vs VMP):意大利MM工作组 PETHEMA/GEM(VMP vs VTP诱导,VT vs VP维持 ):西班牙骨髓瘤工作组,This study was undertaken in 63 Spanish centres between March, 2006, and October, 2008. * * 治疗流程 新药 诱导治疗 维持治疗 初诊MM 65 岁 N=255 随 机 MPT-T (n=129),4周/6疗程 马法兰 4mg/m2 d1-7 泼尼松 40mg/m2 d1-7 沙利度胺 100mg/d 持续直至疾病进展 MP (n=126),4周/6疗程 马法兰 4mg/m2 d1-7 泼尼松 40mg/m2 d1-7 Palumbo A et al. Lancet 2006; 367:825-831. 对于高龄的MM病人:口服 MPT是有效的一线治疗方案。 ≥PR ≥nCR 2年EFS 3年OS ≥3级AE MPT-T 76.0% 27.9% 54% 80% 48% MP 47.6% 7.2% 27% 64% 25% p值 0.0006 0.19 0.0002 Lancet 2006; 367: 825–31 Blood. 2011;118(22):5759-5766 NDMM ≥65ys Randamized Vel 1.3mg/m2 d1,4, 8, 11, 22, 25, 29, 32 Mel 9mg/m2 d1-4 Pred 60mg/m2 d1-4 Thal 50mg/d Induction, Q6w, cycles1-4 mainte
您可能关注的文档
- 课件:磁共振胰胆管造影.ppt
- 课件:胆道梗阻.ppt
- 课件:胆道系统CT诊断.ppt
- 课件:贝伐单抗在肺癌应用中的全程管理.ppt
- 课件:CTA、DSA、MRA及动脉瘤.ppt
- 课件:LC术后护理.ppt
- 课件:慢性肾衰竭的防治策略.pptx
- 课件:PTCD及胆道内支架临床应用.ppt
- 课件:肿瘤的生长与扩散.ppt
- 课件:噪声、热指数、IAQ国际标准.ppt
- 2024-2030年零售银行项目商业计划书.docx
- 2024-2030年非商业丙烯酸涂料行业市场发展趋势与前景展望战略分析报告.docx
- 2024-2030年雨伞行业市场深度调研及发展趋势与投资研究报告.docx
- 2024-2030年零售核心银行系统行业市场现状供需分析及重点企业投资评估规划分析研究报告.docx
- 中国圣洁莓提取物行业市场现状分析及竞争格局与投资发展研究报告(2024-2030版).docx
- 中国地质工程行业市场深度调研及发展前景与投资前景研究报告.docx
- 中国喷雾除尘系统行业市场现状分析及竞争格局与投资发展研究报告(2024-2030版).docx
- 中国虚拟医院行业市场深度调研及发展趋势与投资前景研究报告.docx
- 区域之间的空间组织教学课件.pptx
- 中国医药产业园区行业市场现状分析及竞争格局与投资发展研究报告(2024-2030版).docx
文档评论(0)